Favorable News Coverage Extremely Likely to Impact TESARO (TSRO) Stock Price – Transcript Daily

This post was originally published on this site

News headlines about TESARO (NASDAQ:TSRO) have been trending positive on Monday, AlphaOne reports. The research firm, a subsidiary of Accern, rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. TESARO earned a daily sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also assigned press coverage about the biopharmaceutical company an impact score of 98 out of 100, meaning that recent press coverage is extremely likely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have impacted AlphaOne’s analysis:

Several equities research analysts recently weighed in on the company. Leerink Swann restated a “market perform” rating on shares of TESARO in a report on Monday, March 20th. Citigroup Inc boosted their target price on TESARO from $151.00 to $232.00 and gave the stock a “buy” rating in a report on Thursday, February 9th. Wedbush boosted their target price on TESARO from $164.00 to $174.00 and gave the stock an “outperform” rating in a report on Tuesday, March 28th. Vetr upgraded TESARO from a “buy” rating to a “strong-buy” rating and set a $178.33 target price for the company in a report on Monday, March 27th. Finally, Robert W. Baird lowered TESARO from an “outperform” rating to a “neutral” rating and boosted their target price for the stock from $127.00 to $182.00 in a report on Monday, February 27th. Eight equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $172.41.

TESARO (NASDAQ:TSRO) traded down 5.02% during mid-day trading on Monday, hitting $137.85. The stock had a trading volume of 395,156 shares. The stock’s 50 day moving average price is $146.88 and its 200 day moving average price is $147.11. TESARO has a one year low of $36.71 and a one year high of $192.94. The firm’s market capitalization is $7.39 billion.

In other TESARO news, VP Edward C. English sold 229 shares of the firm’s stock in a transaction on Thursday, March 2nd. The stock was sold at an average price of $177.61, for a total transaction of $40,672.69. Following the transaction, the vice president now owns 625 shares in the company, valued at approximately $111,006.25. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Edward C. English sold 10,000 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $178.06, for a total value of $1,780,600.00. Following the transaction, the vice president now owns 5,396 shares in the company, valued at approximately $960,811.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,432 shares of company stock worth $2,902,602. Corporate insiders own 40.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Favorable News Coverage Extremely Likely to Impact TESARO (TSRO) Stock Price” was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://transcriptdaily.com/2017/05/08/favorable-news-coverage-extremely-likely-to-impact-tesaro-tsro-stock-price.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO




Receive News & Ratings for TESARO Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TESARO Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

This post was originally published on *this site*